Meeting
2023 ASCO Genitourinary Cancers Symposium
Real world analysis of peritoneal metastasis from renal cell carcinoma: Meet-Uro 27 study.
Authors
Marco Stellato
Medical Oncology Department, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy
Marco Stellato , Sebastiano Buti , Marco Maruzzo , Giuseppe Fotia , Mariella Sorarù , Maria Bassanelli , Brigida Anna Maiorano , Francesco Grillone , Luca Galli , Roberto Filippi , Martina Fanelli , Michele Dionese , Michele Maffezzoli , Bruno Vincenzi , Giuseppe Procopio , Elena Verzoni
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session C: Renal Cell Cancer; Adrenal, Penile, Urethral and Testicular Cancers
Track
Renal Cell Cancer,Adrenal Cancer,Penile Cancer,Testicular Cancer,Urethral Cancer
Sub Track
Quality of Care/Quality Improvement and Real-World Evidence
Citation
J Clin Oncol 41, 2023 (suppl 6; abstr 638)
DOI
10.1200/JCO.2023.41.6_suppl.638
Abstract #
638
Poster Bd #
F8
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Genitourinary Cancers Symposium
A multicenter real-world study reviewing systemic anticancer treatment choices and drop off rates between treatment lines for metastatic renal cell carcinoma in the United Kingdom: In the immunotherapy era.
First Author: John McGrane
Poster
2022 ASCO Genitourinary Cancers Symposium
Real-world assessment of changing treatment patterns and sequence for patients with metastatic renal cell carcinoma (mRCC) in the first-line (1L) setting.
First Author: Neil J. Shah
Poster
2020 Genitourinary Cancers Symposium
Second-line VEGF TKI after IO combination therapy: Results from the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC).
First Author: Igor Stukalin
Poster
2015 Genitourinary Cancers Symposium
Comparative effectiveness of first-line VEGF TKI followed by second-line therapy with either a VEGF TKI or an mTOR inhibitor in patients with metastatic renal cell carcinoma.
First Author: Shiven B. Patel